Abstracts tagged "complement and flow cytometry"

Abstract Number: 680 • 2017 ACR/ARHP Annual Meeting
Abnormalities in Complement System Are Related to Disease Severity in Systemic Lupus Erythematosus (SLE)
Cristina Arriens¹, Sonali Narain², Amit Saxena³, Christopher E. Collins⁴, Daniel J. Wallace⁵, Elena Massarotti⁶, John Conklin⁷, Roberta Alexander⁷, Kenneth C. Kalunian⁸, Chaim Putterman⁹, Rosalind Ramsey-Goldman¹⁰, Jill P. Buyon¹¹, Anca Askanase¹², Richard Furie², Susan Manzi¹³, Joseph Ahearn¹⁴, Arthur Weinstein¹⁵ and Thierry Dervieux⁷, ¹Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Northwell Health, Great Neck, NY, ³Rheumatology, NYU Langone Medical Center, New York, NY, ⁴Rheumatology, MedStar Washington Hospital Center, Washington, DC, ⁵Cedars-Sinai Medical Center, UCLA, Los Angeles, CA, ⁶Brigham and Women's Hospital, Boston, MA, ⁷Exagen Diagnostics, Inc., Vista, CA, ⁸Division of Rheumatology, Allergy and Immunology, UCSD School of Medicine, La Jolla, CA, ⁹Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY, USA, Bronx, NY, ¹⁰FSM, Northwestern University, Chicago, IL, ¹¹Medicine, New York University School of Medicine, New York, NY, ¹²Rheumatology, Columbia University, New York, NY, ¹³Medicine, Allegheny Health Network, Pittsburgh, PA, ¹⁴Lupus Center of Excellence, West Penn Allegheny Health System, Pittsburgh, PA, ¹⁵Rheumatology, MedStar Washington Hospital Center/Georgetown University Medical Center, Washington, DC
Background/Purpose: We sought to evaluate the relationships between low complement C3 and C4 proteins, abnormal complement activation (cell-bound complement activation products [CB-CAPs]), and a Lupus…
Abstract Number: 682 • 2017 ACR/ARHP Annual Meeting
Complement Activation in Peripheral Blood in Relation to Lupus, Antiphospholipid and Rheumatoid Arthritis Autoantibodies: Insights from Clinical Laboratory Evaluations
Thierry Dervieux¹, John Conklin¹, JoAnne Ligayon¹, Rowena Lafon², Armida Sace³, Tyler O'Malley⁴, Roberta Alexander¹ and Claudia Ibarra¹, ¹Exagen Diagnostics, Inc., Vista, CA, ²Immunochemistry, Exagen Diagnostics, Inc., Vista, CA, ³Automated Chemistry, Exagen Diagnostics, Inc., Vista, CA, ⁴Research and Development, Exagen Diagnostics, Inc., Vista, CA
Background/Purpose: Abnormal activation of the complement system is emerging as a useful biomarker in the evaluation of patients presenting symptoms of autoimmune rheumatic diseases. We…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].